pubmed-article:18405987 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:18405987 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
pubmed-article:18405987 | lifeskim:mentions | umls-concept:C0012242 | lld:lifeskim |
pubmed-article:18405987 | lifeskim:mentions | umls-concept:C1518578 | lld:lifeskim |
pubmed-article:18405987 | lifeskim:mentions | umls-concept:C0152018 | lld:lifeskim |
pubmed-article:18405987 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
pubmed-article:18405987 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
pubmed-article:18405987 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
pubmed-article:18405987 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
pubmed-article:18405987 | lifeskim:mentions | umls-concept:C0443196 | lld:lifeskim |
pubmed-article:18405987 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
pubmed-article:18405987 | pubmed:issue | 3 | lld:pubmed |
pubmed-article:18405987 | pubmed:dateCreated | 2008-6-18 | lld:pubmed |
pubmed-article:18405987 | pubmed:abstractText | A dose-escalation study of docetaxel combined with cisplatin, 5-fluorouracil, and concurrent radiotherapy (DCF-R) was performed to determine the optimal dose in patients with advanced esophageal carcinoma. | lld:pubmed |
pubmed-article:18405987 | pubmed:language | eng | lld:pubmed |
pubmed-article:18405987 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18405987 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:18405987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18405987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18405987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18405987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18405987 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:18405987 | pubmed:month | Jun | lld:pubmed |
pubmed-article:18405987 | pubmed:issn | 0167-8140 | lld:pubmed |
pubmed-article:18405987 | pubmed:author | pubmed-author:HayakawaKazus... | lld:pubmed |
pubmed-article:18405987 | pubmed:author | pubmed-author:KoizumiWasabu... | lld:pubmed |
pubmed-article:18405987 | pubmed:author | pubmed-author:TanabeSatoshi... | lld:pubmed |
pubmed-article:18405987 | pubmed:author | pubmed-author:SasakiTohruT | lld:pubmed |
pubmed-article:18405987 | pubmed:author | pubmed-author:KatadaChikato... | lld:pubmed |
pubmed-article:18405987 | pubmed:author | pubmed-author:HiguchiKatsuh... | lld:pubmed |
pubmed-article:18405987 | pubmed:author | pubmed-author:IshiyamaHirom... | lld:pubmed |
pubmed-article:18405987 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:18405987 | pubmed:volume | 87 | lld:pubmed |
pubmed-article:18405987 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:18405987 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:18405987 | pubmed:pagination | 398-404 | lld:pubmed |
pubmed-article:18405987 | pubmed:meshHeading | pubmed-meshheading:18405987... | lld:pubmed |
pubmed-article:18405987 | pubmed:meshHeading | pubmed-meshheading:18405987... | lld:pubmed |
pubmed-article:18405987 | pubmed:meshHeading | pubmed-meshheading:18405987... | lld:pubmed |
pubmed-article:18405987 | pubmed:meshHeading | pubmed-meshheading:18405987... | lld:pubmed |
pubmed-article:18405987 | pubmed:meshHeading | pubmed-meshheading:18405987... | lld:pubmed |
pubmed-article:18405987 | pubmed:meshHeading | pubmed-meshheading:18405987... | lld:pubmed |
pubmed-article:18405987 | pubmed:meshHeading | pubmed-meshheading:18405987... | lld:pubmed |
pubmed-article:18405987 | pubmed:meshHeading | pubmed-meshheading:18405987... | lld:pubmed |
pubmed-article:18405987 | pubmed:meshHeading | pubmed-meshheading:18405987... | lld:pubmed |
pubmed-article:18405987 | pubmed:meshHeading | pubmed-meshheading:18405987... | lld:pubmed |
pubmed-article:18405987 | pubmed:meshHeading | pubmed-meshheading:18405987... | lld:pubmed |
pubmed-article:18405987 | pubmed:meshHeading | pubmed-meshheading:18405987... | lld:pubmed |
pubmed-article:18405987 | pubmed:meshHeading | pubmed-meshheading:18405987... | lld:pubmed |
pubmed-article:18405987 | pubmed:meshHeading | pubmed-meshheading:18405987... | lld:pubmed |
pubmed-article:18405987 | pubmed:year | 2008 | lld:pubmed |
pubmed-article:18405987 | pubmed:articleTitle | A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501). | lld:pubmed |
pubmed-article:18405987 | pubmed:affiliation | Department of Gastroenterology, and Kitasato University School of Medicine, Kanagawa, Japan. k.higu@kitasato-u.ac.jp | lld:pubmed |
pubmed-article:18405987 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:18405987 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18405987 | lld:pubmed |